1. Home /
    2. Altai Protocol Library /
  2. New Drug: Trilaciclib to reduce frequency of chemotherapy-induced bone marrow suppression

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Drug: Trilaciclib to reduce frequency of chemotherapy-induced bone marrow suppression

New Drug: Trilaciclib to reduce frequency of chemotherapy-induced bone marrow suppression
Study:
  • Randomized, double-blind phase II trial
  • First-line for metastatic small cell carcinoma
  • CARBOplatin-Etoposide-Atezolizumab backbone. Trilaciclib vs. placebo infused once daily prior to chemo on days 1-3
Efficacy:
  • Mean duration of severe neutropenia: 0 days vs. 4 days (Mean difference 3.6 days [2.3-4.9 days])
  • Severe neutropenia: 1 patient vs. 26 pts (p<0.0001)
  • Pts requiring G-CSF: 29.6% vs. 47.2% (p = 0.0686)
Safety:
  • Grade 3/4 anemia: 18.5 vs. 28.3% (NS)
  • Grade 3/4 thrombocytopenia: 1.9% vs. 37.7% (p=0.0026)
  • Non-heme grade 3/4 AEs: Asthenia (7.7% vs. 3.8%), pneumonia (5.8% vs. 13.2%)
J Clin Oncol 2020 Dec 23. Online ahead of print.
Kopetz S, et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
https://doi.org/10.1200/JCO.20.01994

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More